Paracetamol During Pregnancy Declared Safe by European Researchers, Rebutting Trump-Era Claims
Table of Contents
- Paracetamol During Pregnancy Declared Safe by European Researchers, Rebutting Trump-Era Claims
- Addressing Concerns Over Autism and Neurodevelopment
- Origins of the Controversy
- Conflicting Research and the Need for Clarity
- The Gold Standard: A Systematic Review and Meta-Analysis
- Robust Data Supports Safety Profile
- Addressing Potential Biases in Previous Studies
- Expert Endorsement and Hope for Resolution
A comprehensive review of existing data has reaffirmed the safety of paracetamol – known as Tylenol in the U.S. – during pregnancy, offering reassurance to expectant mothers following unsubstantiated claims linking the pain reliever to developmental disorders. Published Saturday in The Lancet Obstetrics, Gynaecology & Women’s Health, the research directly addresses concerns raised last year by former U.S. President Donald Trump.
Addressing Concerns Over Autism and Neurodevelopment
The study, led by Professor Asma Khalil of City St George’s, University of London, meticulously examined the available evidence to determine any causal link between paracetamol use during pregnancy and the risk of autism, ADHD (attention-deficit/hyperactivity disorder), or intellectual disability. “Paracetamol is safe to use in pregnancy,” Professor Khalil stated unequivocally. “The key message is reassurance: When used as recommended, the best available evidence does not support a causal link with autism, ADHD or intellectual disability.”
Origins of the Controversy
The renewed scrutiny of paracetamol stemmed from comments made by President Trump in September, advising pregnant women to avoid the medication. These statements were widely criticized by medical professionals as lacking any scientific basis. A spokesperson for the U.S. Department of Health and Human Services acknowledged that “many experts have expressed concern of the use of acetaminophen during pregnancy,” but the European study provides a robust counterpoint.
Conflicting Research and the Need for Clarity
Recent research has presented a mixed picture regarding the potential risks of acetaminophen use during pregnancy. A 2024 study conducted in Sweden found no causal connection to neurodevelopmental disorders. However, a 2025 review by U.S. researchers suggested a possible link, advising continued use only at the lowest effective dose and for the shortest duration.
The Gold Standard: A Systematic Review and Meta-Analysis
To resolve this ambiguity, Professor Khalil’s team conducted a systematic review and meta-analysis of 43 existing studies. These studies were rigorously assessed for quality and potential bias using established methodologies. A key component of their analysis focused on studies comparing children born to the same mother – some exposed to paracetamol during pregnancy and others not. This approach effectively controls for shared genetic factors and family environments that could influence the development of autism or other conditions.
Robust Data Supports Safety Profile
The analysis included data covering over 260,000 children assessed for autism, and approximately 335,000 and 405,000 assessed for ADHD and intellectual disabilities, respectively. The results revealed no significant association between paracetamol use and any of the conditions studied. This finding remained consistent even when data from all high-quality studies were combined.
Addressing Potential Biases in Previous Studies
Professor Khalil emphasized that previous research suggesting a link between paracetamol and neurodevelopmental issues often suffered from methodological flaws and confounding factors. Her team’s review was specifically designed to account for these limitations, including those present in the 2025 review of 46 studies cited by Trump officials.
Expert Endorsement and Hope for Resolution
The study has been lauded by experts in the field. Grainne McAlonan, professor of Translational Neuroscience at King’s College London, who was not involved in the research, expressed optimism that the findings would “bring the matter to a close.”
This research provides critical reassurance for pregnant women and underscores the importance of evidence-based medical guidance. Paracetamol remains the only pain reliever generally considered safe for use during pregnancy, though doctors continue to advise cautious application. Untreated pain and fever can pose risks to both mother and developing baby, making informed decisions about pain management essential.
Keep reading
